quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

AMD outlines path to >60% annual data center growth and multi-billion AI revenue by 2027 as MI400 and Helios launch

View original at seekingalpha.com
AMD outlines path to >60% annual data center growth and multi-billion AI revenue by 2027 as MI400 and Helios launch Earnings Call Insights: Advanced Micro Devices (AMD) Q4 2025 MANAGEMENT VIEW * Lisa Su, Chair, President & CEO, opened by stating 2025 was "a defining year for AMD with record revenue, net income and free…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In the longer term, each successive GPU generation should have a higher gross margin.

    80% confidence
  • Greater than 60% Data Center growth is certainly possible in 2026.

    80% confidence
  • AMD is well positioned to grow Data Center segment revenue by more than 60% annually over the next 3 to 5 years and scale AI business to tens of billions in annual revenue in 2027.

    80% confidence
  • AMD has a very strong relationship with OpenAI and is planning the GPU ramp starting in the second half of 2026 going into 2027.

    80% confidence
  • AMD sees a clear path to achieve revenue CAGR greater than 35% over the next 3 to 5 years, significantly expanding operating margins and generating annual EPS of more than $20.

    80% confidence
  • AMD is not forecasting any additional revenue from China due to the dynamic situation.

    80% confidence
  • AMD does not believe it will be supply limited in terms of the ramp that has been put in place.

    80% confidence
  • Q4 2025 diluted non-GAAP EPS was a record $1.53, an increase of 40% year-over-year.

    80% confidence
  • Q4 2025 revenue was a record $10.3 billion, growing 34% year-over-year, driven by strong growth in Data Center and Client and Gaming, including approximately $390 million in MI308 China revenue not included in prior guidance.

    80% confidence
  • The OpenAI MI450 ramp is on schedule to start in the second half of 2026, with MI450 doing great and Helios doing well.

    80% confidence
  • The gaming segment is expected to face significant double-digit percentage decline in semi-custom SoC annual revenue in 2026 due to the mature console cycle.

    80% confidence
  • The MI400 series and Helios platform represent a major inflection point for AMD's business.

    80% confidence
  • AMD closed $17 billion in embedded design wins in 2025, up nearly 20% year-over-year, with more than $50 billion of embedded designs won since acquiring Xilinx.

    80% confidence
  • 8 of the top 10 AI companies use AMD Instinct to power production workloads.

    80% confidence
  • 2025 was a defining year for AMD with record revenue, net income and free cash flow driven by broad-based demand for high-performance computing and AI products.

    80% confidence
  • Memory and component inflationary pressures, including commodity memory pricing, represent potential headwinds.

    80% confidence
  • AMD's OpEx should grow slower than revenue in 2026, consistent with its long-term model.

    80% confidence
  • For 2026, the vast majority of MI455 revenue will come from Rack Scale solutions, with revenue recognized upon shipment to rack builders.

    80% confidence
  • AMD delivered full-year 2025 record revenue of $34.6 billion, up 34% year-over-year, with gross margin of 52% and record EPS of $4.17, up 26% year-over-year.

    80% confidence
  • AMD has increased supply capacity for server CPUs in response to demand trends over the last couple of quarters.

    80% confidence
  • AMD Q1 2026 revenue guidance is approximately $9.8 billion (+/- $300M), including approximately $100M of MI308 sales to China, expected to be up 32% year-over-year.

    80% confidence
  • AMD Data Center segment revenue increased 39% year-over-year to a record $5.4 billion in Q4 2025, led by accelerating Instinct MI350 Series GPU deployments and server share gains.

    80% confidence
  • AMD is working closely with memory and component suppliers over a multi-year time frame to align supply with demand and GPU development roadmaps.

    80% confidence
  • Q4 2025 gross margin was 57%, up 290 basis points year-over-year, benefiting from a $360M release of previously written-down MI308 inventory reserves. Excluding that and China MI308 revenue, gross margin would have been approximately 55%.

    80% confidence
  • Q1 2026 non-GAAP gross margin is expected to be approximately 55% and non-GAAP operating expense approximately $3.05 billion.

    80% confidence
  • Even if the PC market is down in 2026 with second-half slightly subseasonal to first half, AMD believes it can grow its PC business.

    80% confidence
  • In Q1 2026, Data Center revenue is expected to be up sequentially, while the CPU business will be down high single digits due to normal seasonality.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
AMD outlines path to >60% annual data center growth and multi-billion AI revenue by 2027 as MI400 and Helios launch — Source | Via News | pt.VIA.NEWS